Bloomage BioTechnology Crescita futura

Future criteri di controllo 4/6

Bloomage BioTechnology prevede che gli utili e i ricavi cresceranno rispettivamente di 34.5% e 17% all'anno. Si prevede che l'EPS crescerà di 34.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.2% in 3 anni.

Informazioni chiave

34.5%

Tasso di crescita degli utili

34.6%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	44.0%
Tasso di crescita dei ricavi	17.0%
Rendimento futuro del capitale proprio	12.2%
Copertura analitica	Good
Ultimo aggiornamento	21 Oct 2024

Aggiornamenti recenti sulla crescita futura

Bloomage BioTechnology Corporation Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 27

Recent updates

After Leaping 40% Bloomage BioTechnology Corporation Limited (SHSE:688363) Shares Are Not Flying Under The Radar

Sep 30

Need To Know: Analysts Just Made A Substantial Cut To Their Bloomage BioTechnology Corporation Limited (SHSE:688363) Estimates

Aug 30

Bloomage BioTechnology Corporation Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 27

Bloomage BioTechnology (SHSE:688363) Seems To Use Debt Quite Sensibly

Jun 02

Weak Statutory Earnings May Not Tell The Whole Story For Bloomage BioTechnology (SHSE:688363)

May 06

Getting In Cheap On Bloomage BioTechnology Corporation Limited (SHSE:688363) Might Be Difficult

May 01

Previsioni di crescita degli utili e dei ricavi

SHSE:688363 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	8,391	1,120	1,106	1,360	13
12/31/2025	7,269	929	1,152	1,144	14
12/31/2024	6,124	707	-687	1,054	12
9/30/2024	5,729	440	-119	739	N/A
6/30/2024	5,811	510	-145	778	N/A
3/31/2024	6,131	635	-24	933	N/A
12/31/2023	6,076	593	-331	700	N/A
9/30/2023	6,260	808	-192	754	N/A
6/30/2023	6,499	922	-357	582	N/A
3/31/2023	6,409	972	-149	654	N/A
12/31/2022	6,359	971	-61	635	N/A
9/30/2022	6,256	904	159	820	N/A
6/30/2022	5,947	895	482	1,131	N/A
3/31/2022	5,426	830	246	1,035	N/A
12/31/2021	4,948	782	492	1,276	N/A
9/30/2021	4,049	764	-30	897	N/A
6/30/2021	3,622	739	-223	792	N/A
3/31/2021	3,042	690	-179	675	N/A
12/31/2020	2,633	646	-58	705	N/A
9/30/2020	2,194	607	-15	539	N/A
6/30/2020	2,024	588	140	482	N/A
3/31/2020	1,898	586	-23	418	N/A
12/31/2019	1,886	586	-85	365	N/A
9/30/2019	1,687	521	-48	367	N/A
6/30/2019	1,512	500	-22	388	N/A
3/31/2019	1,338	437	83	326	N/A
12/31/2018	1,263	424	274	442	N/A
6/30/2018	988	330	N/A	470	N/A
3/31/2018	903	276	N/A	407	N/A
12/31/2017	818	222	N/A	343	N/A
6/30/2017	817	201	N/A	273	N/A
3/31/2017	830	214	N/A	228	N/A
12/31/2016	733	269	N/A	242	N/A
9/30/2016	801	214	N/A	144	N/A
6/30/2016	757	199	N/A	105	N/A
3/31/2016	704	195	N/A	132	N/A
12/31/2015	651	190	N/A	159	N/A
9/30/2015	600	184	N/A	153	N/A
6/30/2015	549	178	N/A	147	N/A
3/31/2015	515	170	N/A	142	N/A
12/31/2014	481	162	N/A	137	N/A
9/30/2014	457	133	N/A	152	N/A
6/30/2014	434	105	N/A	166	N/A
3/31/2014	404	100	N/A	161	N/A
12/31/2013	375	94	N/A	155	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 688363 ( 34.5% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 688363 ( 34.5% all'anno) cresceranno più rapidamente del mercato CN ( 25.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 688363 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 688363 ( 17% all'anno) crescerà più rapidamente del mercato CN ( 14.1% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 688363 ( 17% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 688363 sarà basso tra 3 anni ( 12.2 %).

Bloomage BioTechnology Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 16%

Price target decreased by 9.1% to CN¥65.43

Bloomage BioTechnology Corporation Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target decreased by 9.9% to CN¥75.39

Price target decreased by 9.9% to CN¥83.72

Price target decreased by 8.6% to CN¥99.40

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 27%

After Leaping 40% Bloomage BioTechnology Corporation Limited (SHSE:688363) Shares Are Not Flying Under The Radar

New minor risk - Share price stability

Bloomage BioTechnology Corporation Limited to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 16%

Now 22% overvalued

Need To Know: Analysts Just Made A Substantial Cut To Their Bloomage BioTechnology Corporation Limited (SHSE:688363) Estimates

Consensus EPS estimates fall by 16%

Bloomage Showcases Key Bioactive Substances At CPHI and HI Korea

Price target decreased by 9.1% to CN¥65.43

Bloomage BioTechnology Corporation Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Bloomage Launches MitoPQQ™ and Presents Hyaluronic Acid Research at IFT FIRST Expo 2024

Bloomage BioTechnology Corporation Limited to Report First Half, 2024 Results on Aug 24, 2024

Bloomage BioTechnology (SHSE:688363) Seems To Use Debt Quite Sensibly

Weak Statutory Earnings May Not Tell The Whole Story For Bloomage BioTechnology (SHSE:688363)

Price target decreased by 9.9% to CN¥75.39

Getting In Cheap On Bloomage BioTechnology Corporation Limited (SHSE:688363) Might Be Difficult

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 9.9% to CN¥83.72

Bloomage BioTechnology Corporation Limited to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 20% overvalued

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 8.6% to CN¥99.40

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates fall by 18%

Consensus revenue estimates fall by 12%

Second quarter 2023 earnings: EPS misses analyst expectations

Bloomage BioTechnology Corporation Limited (SHSE:688363) announces an Equity Buyback for CNY 300 million worth of its shares.

Bloomage BioTechnology Corporation Limited to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 7.9% to CN¥120

Price target decreased by 8.2% to CN¥126

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥150

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to CN¥168

Second quarter 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥153

Price target decreased to CN¥181

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥196

Price target decreased to CN¥239

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.35 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.33 in 2Q 2020)

Price target increased to CN¥245

First quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.23 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.35 (vs CN¥1.34 in FY 2019)

New 90-day low: CN¥134

New 90-day high: CN¥208

New 90-day high: CN¥192

Price target raised to CN¥175

New 90-day high: CN¥150

Bloomage BioTechnology Corporation Limited to Report Q3, 2020 Results on Oct 30, 2020

Bloomage BioTechnology Corporation Limited (SHSE:688363) completed the acquisition of Dongying Fusite Biological Engineering Co., Ltd. from Eastar Holdings Group CO.,LTD and Zhang Zhenwu.

New 90-day low - CN¥119

First half earnings released

Bloomage BioTechnology Corporation Limited to Report First Half, 2020 Results on Aug 26, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita